title: 32P-pyrophosphate in the treatment of persistent metastatic bone pain.
abstract: Eight patients with persistent pain due to disseminated bone metastases from mammary carcinoma were given about 370 MBq (10 mCi) of 32P-pyrophosphate on 10 occasions. All but one of the patients experienced alleviation of pain lasting 1 to 4 months. The side effects, which derived mainly from haematopoetic tissue, prevent the routine use of this compound.
mesh_terms: D001772:Blood Cell Count; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000532:radiotherapy; D011756:Diphosphates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010166:Palliative Care; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*
chemical_list: D011756:Diphosphates; D010761:Phosphorus Radioisotopes